Melanogenesis-targeted anti-melanoma pro-drug development: Effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system
- 1 January 1997
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (1), 135-143
- https://doi.org/10.1016/s0959-8049(96)00340-1
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Phase I study of intravenous 4-hydroxyanisoleEuropean Journal Of Cancer, 1992
- In vitro assessment of the structure – activity relationship of tyrosinase-dependent cytotoxicity of a series of substituted phenolsMelanoma Research, 1991
- Melanogenesis: a realistic target for antimelanoma therapy?European Journal of Cancer and Clinical Oncology, 1991
- Mechanism of toxicity of the antimelanoma drug 4-hydroxyanisole in mouse hepatocytesEuropean Journal of Cancer and Clinical Oncology, 1991
- Initial Mushroom Tyrosinase‐Catalysed Oxidation Product of 4‐Hydroxyanisole is 4‐Methoxy‐Ortho‐BenzoquinonePigment Cell Research, 1988
- Major Primary Cytotoxic Product of 4‐Hydroxyanisole Oxidation by Mushroom Tyrosinase Is 4‐Methoxy Ortho BenzoquinonePigment Cell Research, 1988
- Radicals and melanomasPhilosophical Transactions of the Royal Society of London. B, Biological Sciences, 1985
- The Melanocytotoxic Action of 4-HydroxyanisoleJournal of Investigative Dermatology, 1975
- Hydroxyanisole depigmentation: In‐vivo studiesThe Journal of Pathology, 1969
- Hydroxyanisole depigmentation: In‐vitro studiesThe Journal of Pathology, 1969